Antidiabetic drugs and kidney disease: Recommendations of the Swiss Society for Endocrinology and Diabetology

Swiss Medical Weekly

Volumn 142, Issue , 2012, Pages

  Zanchi, Anne ^a   Lehmann, Roger ^b   Philippe, Jacques ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Diabetic nephropathy; Hypoglycaemic drugs; Renal failure

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; DIAMICRON MR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ACIDOSIS; ACUTE KIDNEY FAILURE; BLADDER CANCER; CARDIOVASCULAR SYMPTOM; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; REVIEW; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DIABETIC NEPHROPATHY; DRUG EFFECT; INCIDENCE; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHYSIOLOGIC MONITORING; PHYSIOLOGY; RISK FACTOR; STANDARD; SWITZERLAND;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MONITORING, PHYSIOLOGIC; RENAL INSUFFICIENCY; RISK FACTORS; SWITZERLAND;

EID: 84866285243     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13629     Document Type: Review

References (25)

1. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-50, (Pubitemid 38543772)
2. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.
3. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011:123:133-43.
4. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-12.
5. Stamm C, Burnier M, Zanchi A. Diabetes and end stage renal disease. Eight year progression in the Canton de Vaud, Switzerland. Rev Med Suisse. 2011;7:495-9.
6. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.
7. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol. 2009;5:397-406.
8. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532-9.
9. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365-70. (Pubitemid 39422090)
10. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial. 2010;23:163-8.
11. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086-91.
12. Lehman R, Fischer-Taescler D, Iselin HU, Pavan M, Pralong F, Seeger R, et al. Directives conernant l'aptitude à conduire lors de diabète sucré. Forum Med Suisse. 2011;11:273-5.
13. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. (Pubitemid 44903747)
14. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380-3.
15. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431-7.
16. von Mach MA, Gauer M, Meyer S, Omogbehin B, Schinzel H, Kann PH, et al. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44:51-6. (Pubitemid 43230586)
17. Padwal RS, Gabr RQ, Sharma AM, Langkaas LA, Birch DW, Karmali S, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34:1295-300.
18. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-56.
19. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947-54.
20. Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65:1230-9.
21. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13:939-46.
22. Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther. 2011;28:447-59.
23. Grouzmann E, Buclin T, Biollaz J. Gliptins. Lancet. 2007;369(9558):269. (Pubitemid 46136475)
24. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516-23.
25. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010;25:2044-7.